Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2004, Pages 15-23

  Webber, C ^a   Stokes, C A ^a   Persiani, S ^b   Makovec, F ^b   McBurney, A ^a   Kapil, R P ^c   John, B A ^a   D'Amato M ^b   Chasseaud, L F ^a  

^a HUNTINGDON LIFE SCIENCES   (United Kingdom)

^b Rotta Research Laboratorium   (Italy)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Cholecystokinin antagonist; Dexloxiglumide; Dogs; Metabolism; Pharmacokinetics

Indexed keywords

CARBON 14; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; DEXLOXIGLUMIDE; GLUCURONIC ACID; O DEMETHYLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ENTEROHEPATIC CIRCULATION; FECES ANALYSIS; FEMALE; GASTROINTESTINAL TRACT; HEMATOCRIT; KIDNEY CLEARANCE; MALE; NONHUMAN; THIN LAYER CHROMATOGRAPHY; TISSUE DISTRIBUTION; URINALYSIS;

EID: 2442549723     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190569     Document Type: Article

References (19)

1. Woodruff G.N. and Hughes, J. (1991): Cholecystokinin antagonists. Ann.Rev.Pharmacol.Toxicol., 31,469-501.
2. D'Amato M., Makovec F., Rovati L.C. (1999b): CCKA-receptors in gastrointestinal disorders. Drug Development: Molecular Targets for GI Diseases, edited by T.S. Gaginella and A. Guglietta, (Totowa, NJ: Human Press) pp. 147-175.
3. Grider J.R. (1994): Role of cholecystokinin in the regulation of gastrointestinal motility. J.Nutrit., 124 (Suppl. 8), 1334S-1339S.
4. Revel L., Makovec F., Castaner J. (1999): Dexloxiglumide-CCK1 (CCKA) receptor antagonist treatment of irritable bowel syndrome. Drugs of the Future, 24, 725-728.
5. Scarpignato C., Kisfalvi I., D'Amato M., and Varga G. (1996): Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Alimen.Pharmacol.Ther., 10, 411-419.
6. Fioramonti J., D'Amato M., Rovati L., Buéno L. (1996) Effects of dexloxiglumide on gastric emptying delayed by colonic distension in dogs.: Neurogastroenterol.Motil., 8, 172.
7. Rouzade M.L., Fioramonti J., D'Amato M., Rovati L., Buéno, L. (1996): Inhibitory action of dexloxiglumide on transient lower oesophageal sphincter relaxation in dogs. Neurogastroenterol.Motil., 8, 188.
8. Meier R., Beglinger C., Giacovelli G., D'Amato M. (1997): Effect of the CCK-A receptor antagonist dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers, Gastroenterol., 112, A788.
9. D'Amato M., Whorwell P.J., Thompson D.G., Spiller R.C., Giacovelli G., Rovati L.C., (1999a): The efficacy and safety of the CCKA-receptor antagonist dexloxiglumide in IBS. Gut, 45 (Suppl.V), A258.
10. D'Amato M., Whorwell P.J., Thompson D.G., Spiller R.C., Giacovelli G., Griffin P.H., Schneier H. and Rovati L.C. (2001): CCK1-receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome. Amer.J.Gastroenterol., 96, S317.
11. Feinle C., Meier O., D'Amato M. (1999): CCK-A Receptor blockade improves dyspeptic symptoms due to duodenal lipid and gastric distension in functional dyspepsia. Gastroenterol., 116, (Suppl.), A992.
12. Webber C., Roth A., Persiani S., Peard A.J., Makovec A., Kapil R.P., John B.A., Holding J.D., D'Amato M., Cybulski Z.R., Chasseaud L.F. and Rovati L.C. (2003): Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica, 33, 625-641.
13. Webber C, Stokes, C.A., Persiani S., Makovec A., McBumey, A., John B.A., Houchen, T.L., D'Amato M. and Chasseaud L.F. (2003): Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat. Eur.J.Drug Metab.Pharmacokinet., 28m 210-212.
14. Davies B. and Morris T. (1993): Physiological parameters in laboratory animals and humans. Pharm.Res., 10, 1093-1095.
15. Hucker H.B., Kwan K.C., Duggan D.E. (1980): Pharmacokinetics and metabolism of non-steroidal anti-inflammatory agents. In Progress in Drug Metabolism, edited by J.W. Bridges and L.F. Chasseaud, (Chichester: Wiley), vol. 5, 165-253.
16. Hirom P.C., Idle J.R. and Millburn P. (1977): Comparative aspects of the biosynthesis and excretion of xenobiotic conjugates by non-primate mammals. In Drug Metabolism - From Microbe to Man, edited by D.V. Parke and R.L. Smith, (London: Taylor and Francis), 299-329.
17. Gibson G.G. and Skett P. (1986): Introduction to Drug Metabolism, (London: Chapman and Hall).
18. Chasseaud L.F. and Hawkins D.R. (1990): Biotransformation of drugs. In Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and J.C. Boylan, (New York: Marcel Dekker), 129-157.
19. Fieser L.F. and Fieser M. (1956): Organic Chemistry, (New York: Reinhold Publishing Corporation).